C-FDA approves IND for D-Pharm's anti-epileptic drug, DP-VPA in China

摘要

D-Pharm Ltd., (TASE: DPRM) have received an approval letter from the Chinese Food and Drug Administration (C-FDA) that allows clinical development of DP-VPA, through Phase 3, for epilepsy. The specific clinical protocols will be communicated to the C-FDA before the start of each new study. Jiangsu Nhwa Pharmaceutical Co., Ltd. (NHWA), its co-development partner, will begin with a bridging safety study and then proceed with a large dose-ranging Phase 2b clinical study in epilepsy patients.